[
  {
    "ts": null,
    "headline": "Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs",
    "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]",
    "url": "https://finnhub.io/api/news?id=040daca37b58183a1104f78ad75b13f4500d449d6715763434e12cc62efb32ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766155822,
      "headline": "Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs",
      "id": 137831377,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]",
      "url": "https://finnhub.io/api/news?id=040daca37b58183a1104f78ad75b13f4500d449d6715763434e12cc62efb32ae"
    }
  },
  {
    "ts": null,
    "headline": "Global Pulmonary Embolism Market Set for Growth with Increasing DVT and PE Cases",
    "summary": "The global pulmonary embolism market is poised for growth from 2025 to 2035, fueled by rising cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) due to escalating obesity rates and sedentary lifestyles. Key drivers include improved diagnostics, Direct Oral Anticoagulants (DOACs), and heightened awareness. Despite the growth, high treatment costs and complications, such as bleeding risks, pose significant challenges, especially in lower-income regions. Top market players include Sano",
    "url": "https://finnhub.io/api/news?id=fc517fc22f504d91709f92b4100028b1da8c6c12ee2e6b00cb8cecedc818a817",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766134860,
      "headline": "Global Pulmonary Embolism Market Set for Growth with Increasing DVT and PE Cases",
      "id": 137831378,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The global pulmonary embolism market is poised for growth from 2025 to 2035, fueled by rising cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) due to escalating obesity rates and sedentary lifestyles. Key drivers include improved diagnostics, Direct Oral Anticoagulants (DOACs), and heightened awareness. Despite the growth, high treatment costs and complications, such as bleeding risks, pose significant challenges, especially in lower-income regions. Top market players include Sano",
      "url": "https://finnhub.io/api/news?id=fc517fc22f504d91709f92b4100028b1da8c6c12ee2e6b00cb8cecedc818a817"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca: Mispriced Growth Following The Oncology Segment Success",
    "summary": "AstraZeneca aims for $80bn revenue by 2030, highlighting oncology advances and growth potential. See AZN stock's valuation insights and GARP investment case.",
    "url": "https://finnhub.io/api/news?id=d922078a6d39841502ab0a542f64330bcda597a46b2e95905ae31285a31da98e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766111433,
      "headline": "AstraZeneca: Mispriced Growth Following The Oncology Segment Success",
      "id": 137828830,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160089493/image_2160089493.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca aims for $80bn revenue by 2030, highlighting oncology advances and growth potential. See AZN stock's valuation insights and GARP investment case.",
      "url": "https://finnhub.io/api/news?id=d922078a6d39841502ab0a542f64330bcda597a46b2e95905ae31285a31da98e"
    }
  }
]